LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Next-Gen IVD LC-MS/MS System 5X More Sensitive for Quantifying Analytes in Saliva, Breath and Dried Blood Spots

By LabMedica International staff writers
Posted on 06 Apr 2023
Image: The new MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (Photo courtesy of Waters)
Image: The new MassTrak IVD LC-MS/MS System featuring the Xevo TQ Absolute IVD tandem quadrupole mass spectrometer (Photo courtesy of Waters)

As energy expenses increase dramatically and laboratory spaces remain in high demand, the need for an analytical instrument that can perform complex trace analyte quantification and increase in-house testing while also reducing energy consumption and saving lab space has become critical. Now, an extremely compact and sustainable analytical instrument accurately quantifies trace analytes with outstanding precision. This powerful instrument can improve patient care, generate cost savings, and meet a laboratory's unique analytical workflow requirements with its vast array of customizable options.

Waters Corporation (Milford, MA, USA) has introduced its next-generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications. The new MassTrak LC-MS/MS IVD system now comprises the ACQUITY UPLC I-Class PLUS liquid chromatography instrument and the Xevo TQ Absolute IVD mass spectrometer. The ACQUITY UPLC I-Class PLUS System is designed to provide fast and precise sample analysis to improve mass spectrometer sensitivity and simplify complex sample characterization. The Xevo TQ Absolute IVD System is more consistent than other tandem quadrupole-mass spectrometry (TQ-MS) systems, with a user-friendly design that maximizes service uptime. Additionally, it is 45% smaller and uses 50% less nitrogen gas and electricity than comparable TQ-MS systems, making it ideal for hospital and commercial labs seeking to reduce energy consumption and save space.

The Xevo TQ Absolute IVD mass spectrometer offers exceptional analytical performance, with up to five times greater sensitivity for quantifying clinical analytes compared to other commercial instruments available. This heightened sensitivity allows clinical laboratories to detect and measure trace-level analytes within a sample, reaching detection levels previously unattainable. This capability expands the testing capabilities of clinical laboratories, making it possible to work with lower volume samples obtained from less invasive assays such as saliva, breath, and dried blood spots. Additionally, the system empowers clinical laboratories to expand their test menu to include multiplex panels and large molecules.

“Waters’ MassTrak IVD systems gives clinical diagnostic laboratories highly precise and flexible options that ultimately enable clinicians to provide better patient care,” said Jianqing Bennett, Waters Corporation Senior Vice President of the Waters Clinical Business Unit. “Adding the Xevo TQ Absolute IVD to the MassTrak IVD family offers customers class-leading sensitivity and analytical performance. Waters is uniquely positioned to enable clinical laboratories to develop reliable test methods for difficult analytes, helping them expand their capabilities to manage emerging remote sampling techniques.”

Related Links:
Waters Corporation 

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more